Suppr超能文献

在急性肝衰竭中桥接治疗与肝移植:来自芬兰的 MARS 10 年经验

Bridging therapies and liver transplantation in acute liver failure, 10 years of MARS experience from Finland.

机构信息

Department of Anaesthesiology and Intensive Care Medicine, Helsinki University Hospital, Helsinki, Finland.

出版信息

Scand J Surg. 2011;100(1):8-13. doi: 10.1177/145749691110000103.

Abstract

Acute liver failure is a life-threatening condition in the absence of liver transplantation option. The aetiology of liver failure is the most important factor determining the probability of native liver recovery and prognosis of the patient. Extracorporeal liver assist devices like MARS (Molecular Adsorbent Recirculating System) may buy time for native liver recovery or serve as bridging therapy to liver transplantation, with reduced risk of cerebral complications. MARS treatment may alleviate hepatic encephalopathy even in patients with a completely necrotic liver. Taking this into account, better prognostic markers than hepatic encephalopathy should be used to assess the need for liver transplantation in acute liver failure.

摘要

急性肝衰竭是一种危及生命的病症,如果没有肝移植的选择。肝衰竭的病因是决定患者自身肝脏恢复的可能性和预后的最重要因素。体外肝脏辅助设备,如 MARS(分子吸附再循环系统),可以为自身肝脏恢复争取时间,或者作为肝移植的桥接治疗,降低脑并发症的风险。MARS 治疗甚至可以缓解完全坏死的肝脏患者的肝性脑病。考虑到这一点,应该使用比肝性脑病更好的预后标志物来评估急性肝衰竭患者是否需要进行肝移植。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验